

and the training necessary to utilize novel manufacturing technologies.

Overall, the FDA Act will reauthorize four user fee programs created to expedite the review of critical medical products that people depend on to live healthier and longer lives.

In addition to delivering drugs and medical devices to people faster, the FDA Act includes policies to lower healthcare costs, spur more lifesaving innovation, secure our supply chains, and provide hope to patients in need of breakthrough drugs and therapies. Those treatments won't make it to patients if FDA doesn't have the right tools to keep up with science, such as accelerated approval pathway.

Chairman PALLONE and I initially had quite different versions for how the accelerated approval process should be updated, but we focused on where we could agree. We streamlined the process to remove drugs that no longer show effectiveness in post-market studies and made sure that real-world evidence can be used. We also made sure rare diseases aren't left out of accelerated approval because of a lack of knowledge and interest in developing the biomarkers necessary.

Lastly, not only is this legislation necessary to preserve patient access to new medical breakthroughs, it is fiscally responsible. It ensures FDA's timely review of medical products at a reduced cost to the taxpayer, and it reduces the deficit.

Many other members have priorities included in this legislation.

Mr. BUCHANAN has a bipartisan bill to make sure that we are moving away from preclinical testing on animal models where alternatives can work just as well.

Messrs. GRIFFITH, CARTER, and HUDSON all have legislation to hold FDA accountable regarding inspections of foreign manufacturing facilities and pilots for FDA to give companies with novel manufacturing technologies more certainty.

Mr. GUTHRIE has a solution included to help insurers plan for breakthrough future treatments. This will help patients avoid sticker shock and protect earlier access to those treatments.

These are just some of more than a dozen examples of member priorities in the FDA Act. I strongly urge support of this legislation, and I encourage all of my colleagues to vote "yes."

Mr. Speaker, this is for patients and families in every district and every corner of America who are relying on a generic drug, a medical device, like a pacemaker, or a novel cancer treatment. Those patients are relying on Congress to do its job so their drug approval isn't stalled.

I think about all the advocates, the hundreds of disease and rare disease groups who come to the people's House to share their stories with us. They have an extraordinary amount of hope in the promise of American innovation for new cures and access to treatments.

For them, I am supporting this legislation, and I am committed to work to get this signed into law on time.

Mr. PALLONE. Madam Speaker, I am prepared to close, and I reserve the balance of my time.

Mr. GUTHRIE. Madam Speaker, I yield myself such time as I may consume.

Madam Speaker, through the years, since this medical device fee has been put into place, has Congress taken action to make sure an agency is efficient; that it does its job to make sure that our drugs and medical devices have efficacy, but also are safe? So we make them more efficient and we have drug companies, device companies, other companies, generic companies, trying to get their devices or their pharmaceuticals approved so they can bring them on the marketplace that are safe and efficient. So this is really an example of Congress working together to move this process forward.

And the innovations that have come out in the last few years, if we look at what has gone on in the diabetes world with the artificial pancreas, all the pumps and insulin devices, to hepatitis C, pharmaceuticals and other ways, and just so much more, what is going to happen in the next 5 years as we continue to move this process forward?

We had a hearing in the Subcommittee on Health on ALS, and we had an ALS patient before us who just wants hope. So all of that is accounted for in this process.

We, as Members of Congress, we, as members of the Committee on Energy and Commerce have worked together to make the process streamlined, to make sure we have efficient, efficacy, and safe products. Our hope and our prayers from this is the science will come into place so those who testified before our committee with rare diseases will have the opportunity and hope to be healed.

I urge my colleagues to support this piece of legislation. A lot of hard work went into it. A lot of lives can be affected by it. I encourage everyone to vote for it.

Madam Speaker, I yield back the balance of my time.

Mr. PALLONE. Madam Speaker, I yield myself such time as I may consume.

Madam Speaker, I couldn't agree more with what Ranking Member GUTHRIE said, and also our full committee ranking member, Mrs. RODGERS. This is a product of a lot of hard work on behalf of members, as well as the staff that are here, and others. It is really great that we are able to do it in a timely fashion because we want the FDA to be able to operate, not to have to put out pink slips because the authorization expires in September.

This is really a reauthorization that does a lot more than just reauthorize the current programs. It really is going to make a difference in terms of our ability to innovate and also affect access to generic drugs.

Madam Speaker, I encourage all Members to support the bill. We are going to work hard to get this passed in the Senate in a timely fashion.

Madam Speaker, I yield back the balance of my time.

The SPEAKER pro tempore (Ms. PINGREE). The question is on the motion offered by the gentleman from New Jersey (Mr. PALLONE) that the House suspend the rules and pass the bill, H.R. 7667, as amended.

The question was taken.

The SPEAKER pro tempore. In the opinion of the Chair, two-thirds being in the affirmative, the ayes have it.

Mr. HARRIS. Madam Speaker, on that I demand the yeas and nays.

The SPEAKER pro tempore. Pursuant to section 3(s) of House Resolution 8, the yeas and nays are ordered.

Pursuant to clause 8 of rule XX, further proceedings on this motion are postponed.

ANNOUNCEMENT BY THE SPEAKER PRO TEMPORE

The SPEAKER pro tempore. Proceedings will resume on questions previously postponed.

Votes will be taken in the following order:

Motions to suspend the rules and pass:

H.R. 6087; and

S. 3823.

The first electronic vote will be conducted as a 15-minute vote. Pursuant to clause 9 of rule XX, remaining electronic votes will be conducted as 5-minute votes.

IMPROVING ACCESS TO WORKERS' COMPENSATION FOR INJURED FEDERAL WORKERS ACT OF 2022

The SPEAKER pro tempore. Pursuant to clause 8 of rule XX, the unfinished business is the vote on the motion to suspend the rules and pass the bill (H.R. 6087) to amend chapter 81 of title 5, United States Code, to cover, for purposes of workers' compensation under such chapter, services by physician assistants and nurse practitioners provided to injured Federal workers, and for other purposes, as amended, on which the yeas and nays were ordered.

The Clerk read the title of the bill.

The SPEAKER pro tempore. The question is on the motion offered by the gentleman from Connecticut (Mr. COURTNEY) that the House suspend the rules and pass the bill, as amended.

The vote was taken by electronic device, and there were—yeas 325, nays 83, not voting 19, as follows:

[Roll No. 233]

YEAS—325

Adams	Bass	Boyle, Brendan
Aderholt	Beatty	F.
Aguilar	Bera	Brooks
Allen	Bergman	Brown (MD)
Allred	Beyer	Brown (OH)
Amodei	Bilirakis	Brownley
Armstrong	Bishop (GA)	Budd
Auchincloss	Blumenauer	Bush
Axne	Blunt Rochester	Bustos
Bacon	Bonamici	Butterfield
Baird	Bost	Calvert
Banks	Bourdeaux	Carbajal
Barragán	Bowman	Cárdenas

Carey	Jackson Lee	Perlmutter		NAYS—83		Thompson (MS)	Trahan	Waters (Garcia
Carl	Jacobs (CA)	Peters	Babin	Gonzales, Tony	Miller (IL)	(Bishop (GA))	(Connolly)	(TX))
Carlson	Jacobs (NY)	Phillips	Balderson	Good (VA)	Miller (WV)	Titus (Connolly)	Vargas (Takano)	Welch (Pallone)
Carter (GA)	Jayapal	Pingree	Barr	Gooden (TX)	Miller-Meeks	Tonko (Pallone)	Walorski (Banks)	Williams (GA)
Carter (LA)	Jeffries	Pocan	Bentz	Gosar	Moolenaar			(Neguse)
Cartwright	Johnson (GA)	Porter	Bice (OK)	Granger	Mooney			Wilson (FL)
Case	Johnson (LA)	Pressley	Biggs	Graves (LA)	Murphy (NC)			(Neguse)
Casten	Johnson (SD)	Price (NC)	Bishop (NC)	Green (TN)	Nehls			
Castor (FL)	Johnson (TX)	Quigley	Boebert	Griffith	Palazzo			
Castro (TX)	Jones	Raskin	Buchanan	Harris	Palmer			
Cawthorn	Joyce (OH)	Reschenthaler	Buck	Hartzler	Pfluger			
Chabot	Kahele	Rice (NY)	Bucshon	Herrell	Posey			
Cherfilus-	Kaptur	Rice (SC)	Burchett	Herrera Beutler	Rose			
McCormick	Katko	Rodgers (WA)	Carter (TX)	Higgins (LA)	Rosendale			
Chu	Keating	Rogers (AL)	Cline	Hill	Roy			
Ciilline	Keller	Rogers (KY)	Cloud	Hudson	Sessions			
Clark (MA)	Kelly (IL)	Ross	Clyde	Jackson	Simpson			
Clarke (NY)	Kelly (MS)	Rouzer	Correa	Johnson (OH)	Steube			
Cleaver	Khanna	Roybal-Allard	Crenshaw	Jordan	Tenney			
Clyburn	Kildee	Ruiz	Cuellar	Joyce (PA)	Van Drew			
Cohen	Kilmer	Ruppersberger	DesJarlais	Kelly (PA)	Van Dwyne			
Cole	Kim (CA)	Rush	Dunn	Kustoff	Walorski			
Comer	Kim (NJ)	Rutherford	Ellzey	LaHood	Weber (TX)			
Connolly	Kind	Ryan	Fallon	LaMalfa	Wenstrup			
Cooper	Kinziger	Salazar	Ferguson	Lamborn	Westerman			
Costa	Kirkpatrick	Sánchez	Franklin, C.	Letlow	Williams (TX)			
Courtney	Krishnamoorthi	Sarbanes	Scott	Lucas	Wilson (SC)			
Craig	Kuster	Scalise	Gaetz	Mann	Wittman			
Crawford	Lamb	Scanlon	Gohmert	Massie	Womack			
Crist	Langevin	Schakowsky						
Crow	Larsen (WA)	Schiff	Arrington	Harder (CA)	Obenolte			
Curtis	Larsen (CT)	Schneider	Brady	Hice (GA)	Perry			
Davids (KS)	Latta	Schrader	Burgess	Higgins (NY)	Schweikert			
Davidson	LaTurner	Schrier	Cammack	Hollingsworth	Webster (FL)			
Davis, Rodney	Lawrence	Scott (VA)	Cheney	Mullin	Yarmuth			
Dean	Lawson (FL)	Scott, Austin	Davis, Danny K.	Norcross				
DeFazio	Lee (CA)	Scott, David	Guest	Norman				
DeGette	Lee (NV)	Sewell						
DeLauro	Leger Fernandez	Sherman						
DelBene	Lesko	Sherrill						
Demings	Levin (CA)	Sires						
DeSaulnier	Levin (MD)	Slotkin						
Deutch	Lieu	Smith (MO)						
Diaz-Balart	Lofgren	Smith (NE)						
Dingell	Long	Smith (NJ)						
Doggett	Loudermilk	Smith (WA)						
Donalds	Lowenthal	Smucker						
Doyle, Michael	Luetkemeyer	Soto						
F.	Luria	Spanberger						
Duncan	Lynch	Spartz						
Emmer	Mace	Speier						
Escobar	Malinowski	Stansbury						
Eshoo	Malliotakis	Stanton						
Espallat	Maloney,	Staubert						
Estes	Carolyn B.	Steel						
Evans	Maloney, Sean	Stefanik						
Feenstra	Manning	Steil						
Fischbach	Mast	Stevens						
Fitzgerald	Matsui	Stewart						
Fitzpatrick	McBath	Strickland						
Fleischmann	McCarthy	Suozzi						
Fletcher	McCaul	Swalwell						
Foster	McClain	Takano						
Fox	McClintock	Taylor						
Frankel, Lois	McCollum	Thompson (CA)						
Fulcher	McEachin	Thompson (MS)						
Gallagher	McGovern	Thompson (PA)						
Gallo	McHenry	Tiffany						
Garamendi	McKinley	Timmons						
Garbarino	McNerney	Titus						
Garcia (CA)	Meeks	Tlaib						
Garcia (IL)	Meijer	Torres (CA)						
Garcia (TX)	Meng	Torres (NY)						
Gibbs	Meuser	Trahan						
Gimenez	Mfume	Trone						
Golden	Moore (AL)	Turner						
Gomez	Moore (UT)	Underwood						
Gonzalez (OH)	Moore (WI)	Upton						
Gonzalez,	Morelle	Valadao						
Vicente	Moulton	Vargas						
Gottheimer	Mrvan	Veasey						
Graves (MO)	Murphy (FL)	Velázquez						
Green, Al (TX)	Nadler	Wagner						
Greene (GA)	Napolitano	Walberg						
Grijalva	Neal	Waltz						
Grothman	Neguse	Wasserman						
Guthrie	Newhouse	Schultz						
Harshbarger	Newman	DeSaulnier						
Hayes	O'Halleran	(Beyer)						
Hern	Ocasio-Cortez	Evans (Beyer)						
Himes	Omar	Frankel, Lois						
Hinson	Owens	(Wasserman						
Horsford	Pallone	Schultz)						
Houlahan	Panetta	DeSaulnier						
Hoyer	Pappas	(Beyer)						
Huffman	Pascrell	Evans (Beyer)						
Huizenga	Payne	Frankel, Lois						
Issa	Pence	(Wasserman						
		Schultz)						
		Gomez (Garcia						
		(TX))						
		Gottheimer						
		(Pallone)						
		Meeks (Jeffries)						

MOMENT OF SILENCE TO HONOR THE VICTIMS OF THE UVALDE SHOOTING

(Mr. TONY GONZALES of Texas asked and was given permission to address the House for 1 minute.)

Mr. TONY GONZALES of Texas. Madam Speaker, on May 24, 2022, 19 children and 2 teachers were killed by a gunman at Robb Elementary School in Uvalde, Texas, my district but a reflection of every small town in America.

As I rise today with my fellow Texans to honor the victims, I am reminded of Matthew 5:4, "Blessed are those who mourn, for they shall be comforted."

I mourn with the Uvalde community and pray for healing and comfort for the families and the community for the loss of:

Alexandria Rubio;
Alithia Ramirez;
Amerie Garza;
Annabelle Rodriguez;
Eliahana Torres;
Eliahna Garcia;
Jacklyn Cazares;
Jailah Silguero;
Jayce Luevanos;
Jose Flores, Jr.;
Layla Salazar;
Makenna Elrod;
Maite Rodriguez;
Maranda Mathis;
Nevaeh Bravo;
Rojelio Torres;
Tess Mata;
Uziyah Garcia;
Xavier Lopez;
Eva Mireles; and
Irma Garcia.

These were our daughters, sons, sisters, brothers, and mothers who have become innocent victims of senseless violence.

Please join us in a moment of silence to honor the victims.

May they rest in peace, and may they always be remembered.

The SPEAKER. The Chair asks all Members in the Chamber, as well as Members and staff throughout the Capitol, to rise for a moment of silence in remembrance of the victims of the recent shootings at Robb Elementary School in Uvalde, Texas.

BANKRUPTCY THRESHOLD ADJUSTMENT AND TECHNICAL CORRECTIONS ACT

The SPEAKER. Pursuant to clause 8 of rule XX, the unfinished business is the vote on the motion to suspend the rules and pass the bill (S. 3823) to amend title 11, United States Code, to modify the eligibility requirements for